Effects of fingolimod treatments on alanine transaminase and aspartate transaminase levels in patients with multiple sclerosis.

Introduction: Multiple Sclerosis (MS) is a chronic neurological disorder with no known cause or cure. Fingolimod (FTY720) is an oral medication recently approved for the treatment of MS as well as other diseases with autoimmune aspects. However, the drug is not without side effects.